Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $31.20.

Several equities research analysts have recently weighed in on AMPH shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, October 8th. Bank of America raised their price objective on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 26th. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a report on Friday, August 8th. Needham & Company LLC lowered their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Zacks Research raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Signaturefd LLC lifted its stake in shares of Amphastar Pharmaceuticals by 147.7% in the 1st quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after acquiring an additional 520 shares during the period. Farther Finance Advisors LLC increased its position in Amphastar Pharmaceuticals by 356.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock worth $25,000 after purchasing an additional 737 shares during the period. Global Retirement Partners LLC raised its stake in shares of Amphastar Pharmaceuticals by 219.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock worth $27,000 after buying an additional 703 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Amphastar Pharmaceuticals by 192.8% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock valued at $29,000 after buying an additional 831 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 3,430.8% in the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock valued at $32,000 after buying an additional 1,338 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $26.06 on Friday. The stock’s 50-day moving average is $25.92 and its two-hundred day moving average is $25.37. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29. Amphastar Pharmaceuticals has a 1 year low of $20.39 and a 1 year high of $46.43. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 9.76 and a beta of 0.77.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.10. The business had revenue of $191.84 million during the quarter, compared to the consensus estimate of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 20.76% and a net margin of 18.64%. Analysts predict that Amphastar Pharmaceuticals will post 3.49 earnings per share for the current year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.